JO
ELDN icon

John Overdeck’s Eledon Pharmaceuticals ELDN Stock Holding History

John Overdeck’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
+32,945
New +$120K ﹤0.01% 4857
2023
Q3 		– Sell
-10,586
Closed -$14.5K – 3014
2023
Q2 		$14.5K Sell
10,586
-7,000
-40% -$14.6K ﹤0.01% 2930
2023
Q1 		$41.5K Sell
17,586
-4,051
-19% -$10.9K ﹤0.01% 2780
2022
Q4 		$49.3K Sell
21,637
-8,100
-27% -$20K ﹤0.01% 2594
2022
Q3 		$82K Sell
29,737
-1,400
-4% -$4.46K ﹤0.01% 2255
2022
Q2 		$76K Sell
31,137
-37,349
-55% -$114K ﹤0.01% 2299
2022
Q1 		$270K Sell
68,486
-56,707
-45% -$220K ﹤0.01% 2245
2021
Q4 		$552K Buy
125,193
+9,869
+9% +$49.9K ﹤0.01% 3153
2021
Q3 		$713K Buy
115,324
+57,814
+101% +$404K ﹤0.01% 2939
2021
Q2 		$455K Buy
57,510
+19,941
+53% +$188K ﹤0.01% 3186
2021
Q1 		$402K Buy
+37,569
New +$567K ﹤0.01% 3119

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

John Overdeck's ELDN Position: Q2 2026 in Review

John Overdeck opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 32,945 shares worth $130K. The stake represents ﹤0.01% of the portfolio and ranks #4857 among its holdings. This is a return to the name: John Overdeck previously reported a position in ELDN as recently as Q2 2023.

John Overdeck first reported a position in ELDN in Q1 2021 and has held it in 11 quarters since. The position peaked at $713K in Q3 2021. 159 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • John Overdeck held 32,945 shares of Eledon Pharmaceuticals worth $130K as of Q2 2026.
  • Eledon Pharmaceuticals was a new John Overdeck position in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4857 holding.
  • John Overdeck first reported a position in Eledon Pharmaceuticals in Q1 2021 and has held it in 11 quarters since.
  • John Overdeck's Eledon Pharmaceuticals position peaked at $713K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.